Centerline Biomedical
United States
- Cleveland, Ohio
- 27/06/2022
- Series B
- $33,000,000
A New Way to Envision Interventional Navigation
- Industry Medical Equipment Manufacturing
- Website https://centerlinebiomedical.com/
- LinkedIn https://www.linkedin.com/company/centerline-biomedical/about/
Related People
Philip D. RackliffeFounder
United States -
Cleveland, Ohio
• 25 years of global healthcare leadership and executive management in medical device, medical technology and pharmaceutical industries spanning public and private sectors
• Successfully grew and scaled companies from start-ups to large multi-nationals, raised millions in capital and bought/sold assets totaling over $1B in proceeds
• General management and P&L ownership from start-ups to company divisions with over $2 billion in annual revenue
• Corporate leadership roles across strategy, sales, marketing (upstream and downstream), business development, operations and global franchises
• Launched more than 50 life sciences products that span both medical device and pharmaceutical sectors
• Keen focus on building strong team cultures by employing a diverse workforce and valuing inclusion at all levels of the organization
• Significant experience in M&A by acquiring and divesting businesses to help drive business synergies
• Extensive international business experience across developed and emerging markets; leading and closing deals in the US, Europe, India, China, Taiwan, Korea and Brazil
• Proven influence capabilities to advance complex business initiatives across a matrixed organization
• Competitive leader that constantly seeks to maximize value for patients and shareholders
• Strong customer intimacy skills gained from starting as a sales professional
• Proud father of two high school aged children, a practicing physician wife and avid tennis player
Canopy(1) | $22,000,000 | (Jan 13, 2026)
Onsetto | $2,200,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Kinaset Therapeutics | $103,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Vibrant Therapeutics | $61,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)